Pancreatic Cancer Research

ResearcherUniversity Hospital in HalleActive in the last 2 years

Marko Damm

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7838-5762; OpenAlex author ID A5037341193. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 10

  1. Pathophysiology, assessment, and treatment of pain in patients with pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00535-026-02423-3↗
  2. Pain profiles in pancreatic cancer and chronic pancreatitis: a multicenter cross-sectional analysis. Last author DOI 10.3389/fpain.2026.1903789↗
  3. Widespread Hyperalgesia Predicts Mortality in Pancreatic Adenocarcinoma First author DOI 10.64898/2026.05.19.26353594↗
  4. Trends in the Treatment and Survival of Pancreatic Cancer: Analysis of 23,339 Patients Diagnosed Between 2010 and 2017. Co-author DOI 10.1002/cam4.71248↗
  5. Pancreatic adenocarcinoma patients with pain have abnormal central pain processing. First author DOI 10.1016/j.pan.2025.04.010↗
  6. Body composition parameters predict survival in pancreatic cancer-A retrospective multicenter analysis. Co-author DOI 10.1002/ueg2.12489↗
  7. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta… Co-author DOI 10.3390/cancers13174326↗
  8. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  9. The quality of pain management in pancreatic cancer: A prospective multi-center study. Co-author DOI 10.1016/j.pan.2020.08.017↗
  10. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonas Rosendahl · 9 shared papers, 2020–2026 · strength 1.62
  2. Patrick Michl · 6 shared papers, 2020–2026 · strength 1.07
  3. Asbjørn Mohr Drewes · 4 shared papers, 2025–2026 · strength 1.03
  4. Vikesh K. Singh · 4 shared papers, 2025–2026 · strength 1.03
  5. Mahya Faghih · 4 shared papers, 2025–2026 · strength 1.03
  6. Søren Schou Olesen · 4 shared papers, 2025–2026 · strength 1.03
  7. Marie-Theres Kassik · 3 shared papers, 2026 · strength 0.80
  8. Anna Evans Phillips · 3 shared papers, 2025–2026 · strength 0.75
  9. Dhiraj Yadav · 3 shared papers, 2025–2026 · strength 0.75
  10. Daniel A. Laheru · 3 shared papers, 2025–2026 · strength 0.75
  11. Sebastian Krug · 3 shared papers, 2021–2025 · strength 0.61
  12. Sophie Rauschenberg · 2 shared papers, 2026 · strength 0.52
  13. Lei Zheng · 2 shared papers, 2025–2026 · strength 0.49
  14. Michael Hirth · 1 shared paper, 2026 · strength 0.28
  15. John A. G. Moir · 3 shared papers, 2020 · strength 0.27
  16. Maximilian Weniger · 3 shared papers, 2020 · strength 0.27
  17. Stephan Schorn · 3 shared papers, 2020 · strength 0.27
  18. Guralp Onur Ceyhan · 3 shared papers, 2020 · strength 0.27
  19. Andrew Derek Hopper · 1 shared paper, 2023 · strength 0.17
  20. Mustafa Jalal · 1 shared paper, 2023 · strength 0.17
  21. Giuseppe Malleo · 2 shared papers, 2020 · strength 0.16
  22. Michael Haas · 2 shared papers, 2020 · strength 0.16
  23. Stephan Krüger · 2 shared papers, 2020 · strength 0.16
  24. Patrick Maisonneuve · 2 shared papers, 2020 · strength 0.16
  25. Maximilian Kordes · 2 shared papers, 2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.